美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Parabilis Medicines

30.31

-1.2900-4.08%

盤後：29.91-0.3997-1.32%19:48 EDT

成交量：160.04萬

成交額：5,174.98萬

市值：35.81億

市盈率：-0.45

高：34.47

開：30.00

低：29.65

收：31.60

52周最高：34.47

52周最低：26.61

股本：1.18億

流通股本：2,500.00萬

量比：0.29

換手率：6.40%

股息：- -

股息率：- -

每股收益(TTM):-67.0858

淨資產收益率：--

總資產收益率：--

市淨率：-6.28

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Parabilis Medicines宣佈完成規模擴大的首次公開募股，承銷商全額行使超額配售權

異動解讀｜Parabilis Medicines盤中上漲49.15%，IPO首日獲10倍超額認購大幅高開

熱門話題-藥物開發商Parabilis Medicines在納斯達克上市首日股價大漲

異動解讀 | 美股IPO上市受熱捧，Parabilis Medicines盤中大漲66.75%

美股異動 | Parabilis Medicines(PBLS.US)登陸美股市場開盤後股價升逾44%

癌症肽療法新星Parabilis(PBLS.US)超區間定價IPO，獲10倍超額認購最終募資7.45億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PBLS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":30.31,"timestamp":1781208000000,"preClose":31.6,"halted":0,"volume":1600443,"hourTrading":{"tag":"盘后","latestPrice":29.9103,"preClose":30.31,"latestTime":"19:48 EDT","volume":52063,"amount":1561437.1007,"timestamp":1781221691036,"change":-0.3997,"changeRate":-0.013187,"amplitude":0.023095},"delay":0,"changeRate":-0.04082278481012667,"floatShares":25000000,"shares":118145780,"eps":-67.08582,"marketStatus":"已收盤","change":-1.29,"latestTime":"06-11 16:00:00 EDT","open":30,"high":34.4706,"low":29.65,"amount":51749780.25438,"amplitude":0.152551,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-67.08582,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1781251200000},"marketStatusCode":5,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":31.6,"preHourTrading":{"tag":"盘前","latestPrice":30.99,"preClose":31.6,"latestTime":"09:25 EDT","volume":4532,"amount":140568.708632,"timestamp":1781184347682,"change":-0.61,"changeRate":-0.019304,"amplitude":0.099051},"postHourTrading":{"tag":"盘后","latestPrice":29.9103,"preClose":30.31,"latestTime":"19:48 EDT","volume":52063,"amount":1561437.1007,"timestamp":1781221691036,"change":-0.3997,"changeRate":-0.013187,"amplitude":0.023095},"volumeRatio":0.291164},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","floatShares":25000000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.291164,"shares":118145780,"dividePrice":0,"high":34.4706,"amplitude":0.152551,"preClose":31.6,"low":29.65,"week52Low":26.61,"pbRate":"-6.28","week52High":34.4706,"institutionHeld":0,"latestPrice":30.31,"eps":-67.08582,"divideRate":0,"volume":1600443,"delay":0,"ttmEps":-67.08582,"open":30,"prevYearClose":20,"prevWeekClose":20,"prevMonthClose":20,"prevQuarterClose":20,"fiveDayClose":20,"twentyDayClose":20,"sixtyDayClose":20},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBLS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBLS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBLS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBLS","date":"2026-06-10","current":-0.451809,"percent":1,"low":-15.535256,"twenty":-15.535256,"median":-15.535256,"eighty":-15.535256,"high":-15.535256,"avg":-15.535256,"sd":0,"marketCap":2375014380},"quantilePoints":[{"date":"2026-06-10","current":-15.535256,"twenty":-15.535256,"median":-15.535256,"eighty":-15.535256,"marketCap":2375014380}],"updateTime":1781231099847},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBLS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1189403882","title":"Parabilis Medicines宣佈完成規模擴大的首次公開募股，承銷商全額行使超額配售權","url":"https://stock-news.laohu8.com/highlight/detail?id=1189403882","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189403882?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 04:06","pubTimestamp":1781208398,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，其规模扩大的首次公开募股（IPO）已正式完成。此次发行中，承销商全额行使了购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120727250","title":"異動解讀｜Parabilis Medicines盤中上漲49.15%，IPO首日獲10倍超額認購大幅高開","url":"https://stock-news.laohu8.com/highlight/detail?id=1120727250","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120727250?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 02:03","pubTimestamp":1781114598,"startTime":"0","endTime":"0","summary":"6月10日，Parabilis Medicines盘中上涨49.15%，报29.83美元/股，成交额1.01亿美元。消息面上，公司当日完成美股IPO并挂牌上市，发行价定为每股20美元，高于此前17-19美元的推介区间，IPO认购需求达可供股份数的约10倍。本次IPO发行3350万股，募资约6.70亿美元；同时再生元制药以每股18美元认购约7500万美元股份，合计筹资近7.45亿美元。Parabilis Medicines是一家临床阶段生物制药公司，专注于开发用于癌症治疗的工程化肽疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478308","title":"熱門話題-藥物開發商Parabilis Medicines在納斯達克上市首日股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478308","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478308?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 01:20","pubTimestamp":1781112027,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL4S42I1G5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2089984988.USD","BK4539","LU2362541513.USD","LU0289739699.SGD","LU0823416689.USD","LU2362540622.SGD","LU2468319806.SGD","LU0114720955.EUR","LU0889565916.HKD","LU0109394709.USD","LU0823434583.USD","NUVL","LU1974910355.USD","REGN","LU2023250504.SGD","LU0882574055.USD","PBLS","LU0320765992.SGD","LU0823434740.USD","LU2362541273.HKD","LU2106854487.HKD","LU0053666078.USD","BK4139","LU1917777945.USD","LU2237438978.USD","BK4588","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104824154","title":"異動解讀 | 美股IPO上市受熱捧，Parabilis Medicines盤中大漲66.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104824154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104824154?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 01:12","pubTimestamp":1781111553,"startTime":"0","endTime":"0","summary":"生物科技公司Parabilis Medicines  今日盘中股价大幅飙升66.75%，成为市场焦点。Parabilis Medicines成立于2015年，专注于开发针对多种癌症及罕见肿瘤的治疗方案，此次IPO募集资金将主要用于推进其最领先的候选药物zolucatetide进入更后期的临床试验阶段，这增强了投资者对公司未来发展的信心。市场分析认为，尽管公司目前处于亏损状态，但其在癌症治疗领域的专业性和IPO带来的资金注入，为其后续的研发和商业化提供了关键支持，从而推动了股价的积极表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478833","title":"美股異動 | Parabilis Medicines(PBLS.US)登陸美股市場 開盤後股價升逾44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478833?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，聚焦癌症治疗的美国生物科技公司Parabilis Medicines(PBLS.US)登陆美股市场，开盘股价走高，截至发稿，该股涨44.35%，报28.87美元。IPO价格为20美元。Parabilis成立于2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。公司拟将IPO募集资金用于推进其最领先候选药物zolucatetide进入更后期临床试验阶段。截至2025财年年末，Parabilis净亏损1.459亿美元，期末现金及现金等价物2,770万美元;前一财年净亏损为1.179亿美元，现金为4,730万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414058","title":"癌症肽療法新星Parabilis(PBLS.US)超區間定價IPO，獲10倍超額認購 最終募資7.45億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642414058?lang=zh_tw&edition=fundamental","pubTime":"2026-06-10 11:30","pubTimestamp":1781062200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines完成了一项规模上调的美股IPO，发行价定在推介区间之上，叠加同步进行的私募配售，合计筹资近 7.45亿美元。在本次周二上调规模前，IPO认购需求已达可供股份数的约10倍。文件显示，截至 2025财年年末，Parabilis 净亏损 1.459亿美元，期末现金及现金等价物 2,770万美元;前一财年净亏损为 1.179亿美元，现金为 4,730万美元。Parabilis 成立于 2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}